TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17350216
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered starting <or=72 hours of the index revascularization and then 5 days per week for 8 weeks)
Study: 12490752
Drug: Study care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study care protocol (no-rinse skin cleanser after each episode and application of a barrier cream with durable properties after the first incontinence episode of each shift)
Study: 12490752
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care regimen (soap and water cleansing after each incontinence episode, followed by application of a moisturizing lotion)
Study: 8013758
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg per os, at -5 and -1 h before the clamp)
Study: 2786673
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g six times per day via gastric tube)
Study: 2786673
Drug: Ranitidine (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (six 50‐mg to six 100‐mg doses per day intravenously)
Study: 5354877
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt) at 55 mug
Study: 5354877
Drug: Isoprenaline sulphate
Normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoprenaline sulphate inhalation at 550 mug
Study: 5354877
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE(1)) inhalation (free acid or neutral triethanolamine salt)
Study: 5354877
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE(1)) inhalation (triethanolamine salt)
Study: 31448013
Drug: Daily follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily follow-up reminder
Study: 31448013
Drug: Incentivised mHealth
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentivised mHealth solution
Study: 28735755
Drug: 30min of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30min of vigorous‐intensity exercise 24h prior to the first doxorubicin treatment
Study: 28735755
Drug: No vigorous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vigorous exercise for 72h prior to treatment (control)
Study: 25896256
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine challenge during a 55-minute resting-state scan
Study: 24379055
Drug: Fixed oral
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed oral combination of hyaluronic acid and chondroitin-sulphate (HA+CS)
Study: 21457209
Drug: Adapalene-benzoyl peroxide
Normalized name: Adapalene-Benzoyl Peroxide Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene-benzoyl peroxide gel
Study: 8093148
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional oral education at outpatient or surgery visits)
Study: 28826348
Drug: Tablet computer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet computer-based intervention
Study: 10357732
Drug: Phytosterol-enriched diet
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-enriched diet (1.7 g phytosterols/d for 30 d)
Study: 8952863
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin administration with tissue plasminogen activator
Study: 8952863
Drug: Subcutaneous or
Normalized name: Vaccinia, smallpox monkeypox vaccine, live attenuated, preservative free, subcutaneous or intradermal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous or intravenous heparin use with streptokinase
Study: 6125205
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine 200 mg or 400 mg
Study: 6125205
Drug: Capsule preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule preparations of diazepam
Study: 26599796
Drug: Saline flush
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline flush (20 mL normal saline) after rocuronium administration
Study: 24271264
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment group (CT, n = 61)
Study: 20400266
Drug: Quebec Back
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quebec Back Pain Disability Scale (administered pre-treatment and post-treatment)
Study: 15529306
Drug: Low‐radiation dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low‐radiation dose spiral computed tomography (LDCT)
Study: 10499652
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (n = 10): standard heparinization (300 IU/kg) plus two doses of purified antithrombin III (1000 IU each)
Study: 10499652
Drug: Group GA
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group GA (n = 10): 200 IU/kg heparin, continuous infusion of heparin (100 IU/kg/h) and gabexate mesilate (2 mg/kg/h) plus the same dose of antithrombin III as group A
Study: 6818588
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg nicotine cigarettes
Study: 6818588
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg nicotine cigarettes
Study: 29089063
Drug: Lotilaner (Credelio™,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotilaner (Credelio™, Elanco) at 20 mg/kg
Study: 29089063
Drug: Afoxolaner (Nexgard®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afoxolaner (Nexgard®, Merial) at 2.5 mg/kg
Study: 26981577
Drug: Oral phage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phage therapy (T4-like coliphages or commercial Russian coliphage product)
Study: 26981577
Drug: Oral phage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral phage therapy
Study: 25066269
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg, intravenous) with mFOLFOX6
Study: 25066269
Drug: Low-dose linifanib
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose linifanib (7.5 mg) with mFOLFOX6
Study: 25066269
Drug: High-dose linifanib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose linifanib (12.5 mg) with mFOLFOX6
Study: 18057338
Drug: Tesamorelin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesamorelin (2 mg daily subcutaneous injection for 26 weeks)
Study: 1391977
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone treatment (Control)
Study: 3999081
Drug: Diumide‐K Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diumide‐K Continus tablets
Study: 3999081
Drug: Lasikal tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasikal tablets
Study: 3999081
Drug: Lasix and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lasix and Slow‐K tablets
Study: 18309618
Drug: Airborne particle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Airborne particle abrasion with 50-microm Al2O3 + Silano-Pen + silane coupling agent (Bredent)
Study: 18309618
Drug: Laboratory tribochemical
Normalized name: guaifenesin
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory tribochemical silica coating (110-microm Al2O3 + 110-microm SiOx) (Rocatec) + silane coupling agent (ESPE-Sil)
Study: 18246859
Drug: Other antidepressant
Normalized name: Other antidepressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antidepressant drugs
Study: 12655908
Drug: Nonteratogenic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonteratogenic drugs
Study: 10984014
Drug: Erdosteine syrup
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine syrup 3.5%
Study: 10984014
Drug: Erdosteine sachets
Normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine sachets 225 mg
Study: 10984014
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for syrup 3.5%)
Study: 10984014
Drug: Placebo (for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (for sachets 225 mg)
Study: 20005744
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil (average effect site concentration 1.99 +/- 0.02 ng/mL) with epidural analgesia with 0.5% ropivacaine started at the beginning of anesthesia
Study: 20005744
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil (average effect-site concentration 5.61 +/- 0.84 ng/mL) with epidural analgesia started and at the end of surgery
Study: 16889593
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy of 10,000 lux/wide spectrum for 3 weeks
Study: 1323624
Drug: Foscarnet maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet maintenance therapy
Study: 1602361
Drug: No chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chronic antiviral therapy
Study: 24577230
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at three doses (200 mg, 400 mg, 800 mg/day) for 12 weeks
Study: 20518807
Drug: Taranabant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant (all doses)
Study: 17952847
Drug: Common single-nucleotide
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Common single-nucleotide polymorphisms (SNPs) in seven genes involved in HDL metabolism
Study: 17952847
Drug: 660 polymorphisms
Normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 660 polymorphisms in eight genes not involved in HDL metabolism
Study: 15817602
Drug: FEC followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FEC followed by high dose therapy (HDT) consisting of cyclophosphamide, thiotepa, and carboplatin with stem cell rescue
Study: 15817602
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (5-fluorouracil, epirubicin, and cyclophosphamide - FEC for six cycles)
Study: 12219032
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous insulin at a rate of at least 1.5 microU/kg/min to maintain serum glucose levels between 100 to 140 mg/dL
Study: 10367025
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate at 300 mg load
Study: 10367025
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate at 300 mg load
Study: 10367025
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate at 1000 mg load
Study: 10367025
Drug: Calcium citrate
Normalized name: Calcium Citrate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium citrate at 1000 mg load
Study: 10367025
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate vs. calcium citrate at 1000 mg load (urinary increment method)
Study: 924791
Drug: Danitracene 1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danitracene 1-3 x 0.5 mg/day for 1-3-6 months
Study: 924791
Drug: Danitracene 1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danitracene 1-3 x 0.5 mg/day
Study: 29088439
Drug: Manual CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual CC
Study: 25743937
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg) with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Study: 25743937
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with docetaxel (75 mg/m²) and prednisone (5 mg twice daily)
Study: 25743937
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg)
Study: 23902779
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and vitamin B-12 combination
Study: 19371315
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg b.i.d. for 7 days
Study: 19371315
Drug: Carbamazepine titrated
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine titrated up to 200 mg b.i.d. over 20 days
Study: 11093555
Drug: Screening plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening plus treatment for those with previous ulcers
Study: 9181277
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion (2 micrograms/kg/min for two hours)
Study: 1327049
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (400 micrograms twice daily for 5 days)
Study: 1327049
Drug: Inhaled PAF
Normalized name: pafuramidine
DrugBank: Pafuramidine (DB06532)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled PAF (total cumulative dose of 500 micrograms)
Study: 3908329
Drug: Disopyramide (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide (7 mg/kg per day)
Study: 3908329
Drug: Amiodarone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (200 mg)
Study: 27161860
Drug: Buprenorphine-naloxone therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine-naloxone therapy for 12 weeks
Study: 22432104
Drug: Lixisenatide 2-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 2-step (10 μg for 1 week, 15 μg for 1 week, then 20 μg)
Study: 22432104
Drug: Lixisenatide 1-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 1-step (10 μg for 2 weeks, then 20 μg)
Study: 20562069
Drug: Elixir DESyne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixir DESyne Novolimus Eluting Coronary Stent System (NES)
Study: 2109927
Drug: Prostacyclin (PGI2)
Normalized name: PGI2
DrugBank: Epoprostenol (DB01240)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostacyclin (PGI2) infusion (5 ng/kg/min for 72 hours)
Study: 7010886
Drug: Acetazolamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (250 mg x 3) added if IOP uncontrolled
Study: 7010886
Drug: Timolol once
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol once a day administration
Study: 31734151
Drug: Foot massage
Normalized name: MENTHOL 13.5 mg in 1 mL TOPICAL LOTION [Foot Works Achy Foot Massager Pain Relieving]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot massage therapy (10-minute sessions, twice during one day, within 30 minutes after opioid pain medication)
Study: 30680852
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of varenicline (extended treatment)
Study: 30680852
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of varenicline plus 12 weeks of placebo (standard treatment)
Study: 26360979
Drug: Verapamil-nitroglycerin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil-nitroglycerin (30 μmol/L each)
Study: 8557121
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH-a)
Study: 19688314
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (ATH group)
Study: 11904526
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clopidogrel and ASA
Study: 10559611
Drug: Oral bropirimine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bropirimine (3 g/day for 3 consecutive days with a 4-day drug-free interval for up to 1 year)
Study: 10559611
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (weekly for 2 x 6 weeks)
Study: 10559611
Drug: Oral bropirimine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bropirimine
Study: 2350615
Drug: Pamidronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (1 mg/kg body wt.) by infusion over 4 h
Study: 2350615
Drug: Pamidronate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (1 mg/kg body wt.) by infusion over 24 h
Study: 7011531
Drug: PIP (6-mercaptopurine
Approvals — FDA: no, EMA: no, PMDA: no
Description: PIP (6-mercaptopurine daily and a prednisone pulse every three months)
Study: 29914146
Drug: Quinoa-enriched bread
Normalized name: quinoa oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinoa-enriched bread (providing 20 g quinoa flour)
Study: 27893654
Drug: Vaccine A
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine A
Study: 27893654
Drug: Vaccine B
Normalized name: meningococcal vaccine B and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine B
Study: 27893654
Drug: Vaccine C
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine C
Study: 27893654
Drug: Vaccine D
Normalized name: hepatitis B adult vaccine dialysis 40 mcg/mL intramuscular suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine D
Study: 20613470
Drug: Remifentanil (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0, 2, and 4 ng/ml)
Study: 14508155
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use and infection control practices
Study: 7793587
Drug: Selective decontamination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective decontamination of the digestive tract (SDD) - parenteral cefotaxime, oral and enteral polymyxin E, tobramycin, and amphotericin B
Study: 28928556
Drug: Total intravenous
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total intravenous anesthesia (TIVA) with propofol (Group II)
Study: 23764350
Drug: siponimod 0.25
Normalized name: siponimod 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 0.25 mg
Study: 23764350
Drug: siponimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 0.5 mg
Study: 23764350
Drug: siponimod 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 1.25 mg
Study: 23764350
Drug: siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: siponimod 2 mg
Study: 23764350
Drug: siponimod 10
Normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: siponimod 10 mg
Study: 15581196
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone (1 mg/daily)
Study: 11722323
Drug: Carbamazepine treatment
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine treatment (stable dose)
Study: 7651920
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment with antiviral drugs
Study: 28301614
Drug: HP/TAZ lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP/TAZ lotion (halobetasol propionate 0.01% and tazarotene 0.045%)
Study: 24169346
Drug: Tivantinib 360
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 360 mg BID with erlotinib for extensive metabolisers (EMs)
Study: 24169346
Drug: Tivantinib 240
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivantinib 240 mg BID with erlotinib for poor metabolisers (PMs)
Study: 24169346
Drug: Pharmacokinetics profile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetics profile of tivantinib
Study: 22087066
Drug: Calligraphy therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calligraphy therapy (intensive calligraphy training for eight weeks)
Study: 22087066
Drug: No calligraphy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No calligraphy treatment (control group)
Study: 18724864
Drug: Non-surgical mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical mechanical periodontal treatment in the second trimester of pregnancy
Study: 16413592
Drug: Trivalent live‐attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent live‐attenuated influenza virus vaccine (LAIV, FluMist)
Study: 15477795
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs with renoprotective properties; specific types include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, beta-blockers, and diuretics; dosage and duration not specified.
Study: 11229849
Drug: Candidate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate vaccines (low, medium, high doses)
Study: 11229849
Drug: Candidate vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate vaccines
Study: 3324618
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg/48 hours) + dipyridamole (300 mg/day)
Study: 3324618
Drug: Dipyridamole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (400 mg/day)
Study: 24001364
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered cognitive behavioural therapy (CBT) for insomnia over 6 weeks
Study: 16152839
Drug: Rhubarb and
Normalized name: Rhubarb and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhubarb and Sanchi Powder (RSP) - 3g of rhubarb and 2g of Sanchi Powder orally, 3-4 times daily